Pfizer's Lyrica Hits Primary Endpoints in Epilepsy Trial
Pfizer released in a press statement yesterday that its anticonvulsant drug Lyrica met the primary endpoints in a phase 3 study judging the medication's effectiveness as an epilepsy therapy for patients with refractory partial onset seizures.
The study showed that Lyrica reduced seizures by at least 50% in an acceptable amount of patients. It also proved Lyrica to be as effective as a comparable treatment, the seizure therapy Keppra.
Refractory partial onset seizures refer to those incidents that medication alone cannot completely control. Lyrica is already approved for a number of other indications around the world, such as fibromyalgia and neuropathic pain. Pfizer's previous studies for the medication's effectiveness against epilepsy have been mixed, however, including a 2012 study involving a once-a-day Lyrica formulation that failed.
The article Pfizer's Lyrica Hits Primary Endpoints in Epilepsy Trial originally appeared on Fool.com.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
